Kodiak Sciences Inc
K27
Company Profile
Business description
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Contact
1200 Page Mill Road
Palo AltoCA94304
USAT: +1 650 281-0850
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
121
Stocks News & Analysis
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
stocks
Most popular shares in SMSFs
With data showing the continued rise of SMSFs, we explore the top stock picks of individual investors
stocks
Will China strong arm BHP into lower iron ore prices?
Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,191.00 | 26.50 | -0.29% |
| CAC 40 | 7,934.26 | 16.26 | 0.21% |
| DAX 40 | 24,387.93 | 146.47 | 0.60% |
| Dow JONES (US) | 46,067.58 | 587.98 | 1.29% |
| FTSE 100 | 9,442.87 | 66.53 | -0.70% |
| HKSE | 25,748.10 | 141.38 | -0.55% |
| NASDAQ | 22,694.61 | 490.18 | 2.21% |
| Nikkei 225 | 47,520.57 | 1,059.87 | -2.18% |
| NZX 50 Index | 13,259.50 | 92.42 | -0.69% |
| S&P 500 | 6,654.72 | 102.21 | 1.56% |
| S&P/ASX 200 | 8,881.90 | 27.80 | -0.31% |
| SSE Composite Index | 3,890.19 | 0.68 | 0.02% |